在一组住院和非住院的COVID-19患者中，奈玛特韦/利托那韦医学禁忌的患病率。
Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.
作者信息
Lim Sarah, Tignanelli Christopher J, Hoertel Nicolas, Boulware David R, Usher Michael G
机构信息
Minnesota Department of Health, St. Paul, Minnesota, USA.
Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
出版信息
Open Forum Infect Dis. 2022 Aug 3;9(8):ofac389. doi: 10.1093/ofid/ofac389. eCollection 2022 Aug.
Abstract
This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.
摘要
该分析描述了在一个大型医疗保健系统中，66007例2019冠状病毒病患者中使用奈玛特韦/利托那韦的禁忌证发生率。9830例患者（14.8%）存在可能的禁忌证，禁忌证的发生率随疾病严重程度的增加而升高。
相似文献
1
Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.
Open Forum Infect Dis. 2022 Aug 3;9(8):ofac389. doi: 10.1093/ofid/ofac389. eCollection 2022 Aug.
2
Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease.
JAMA Netw Open. 2022 Nov 1;5(11):e2242140. doi: 10.1001/jamanetworkopen.2022.42140.
3
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Antibiotics (Basel). 2022 Feb 9;11(2):220. doi: 10.3390/antibiotics11020220.
4
Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19.
SAGE Open Med Case Rep. 2023 Apr 20;11:2050313X231168304. doi: 10.1177/2050313X231168304. eCollection 2023.
5
Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study.
Infect Chemother. 2022 Dec;54(4):757-764. doi: 10.3947/ic.2022.0123. Epub 2022 Nov 18.
6
Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data.
Drugs Context. 2023 Jun 27;12. doi: 10.7573/dic.2023-3-4. eCollection 2023.
7
In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.
Ann Intern Med. 2022 Jun;175(6):JC63. doi: 10.7326/J22-0038. Epub 2022 Jun 7.
8
Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal.
Open Forum Infect Dis. 2022 May 13;9(7):ofac238. doi: 10.1093/ofid/ofac238. eCollection 2022 Jul.
9
Oral Drugs Against COVID-19.
Dtsch Arztebl Int. 2022 Apr 15;119(15):263-269. doi: 10.3238/arztebl.m2022.0152.
10
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy.
Epilepsia. 2022 May;63(5):1276-1278. doi: 10.1111/epi.17212. Epub 2022 Mar 9.
引用本文的文献
1
Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.
J Pers Med. 2025 Apr 17;15(4):156. doi: 10.3390/jpm15040156.
2
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
3
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
BMC Infect Dis. 2024 Aug 8;24(1):802. doi: 10.1186/s12879-024-09708-z.
4
Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana.
Open Forum Infect Dis. 2024 Jul 2;11(7):ofae344. doi: 10.1093/ofid/ofae344. eCollection 2024 Jul.
5
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
J Korean Med Sci. 2024 Feb 19;39(6):e52. doi: 10.3346/jkms.2024.39.e52.
6
An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.
Int J Mol Sci. 2023 Dec 26;25(1):354. doi: 10.3390/ijms25010354.
7
Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.
Pharmaceuticals (Basel). 2023 Aug 4;16(8):1107. doi: 10.3390/ph16081107.
8
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.
J Med Chem. 2023 Sep 14;66(17):12237-12248. doi: 10.1021/acs.jmedchem.3c00810. Epub 2023 Aug 18.
9
Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data.
Lancet Reg Health West Pac. 2023 May;34:100716. doi: 10.1016/j.lanwpc.2023.100716. Epub 2023 Feb 27.
10
The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
Viruses. 2023 Apr 16;15(4):976. doi: 10.3390/v15040976.
本文引用的文献
1
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
2
Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines.
Vaccines (Basel). 2021 Aug 17;9(8):914. doi: 10.3390/vaccines9080914.
3
Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions.
Am J Kidney Dis. 2010 Apr;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337.
4
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Clin Pharmacokinet. 1998 Oct;35(4):275-91. doi: 10.2165/00003088-199835040-00002.
Zotero 插件